GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (MEX:INCY) » Definitions » Loans Receivable

Incyte (MEX:INCY) Loans Receivable : MXN0 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Incyte Loans Receivable?

Incyte's Loans Receivable for the quarter that ended in Mar. 2025 was MXN0 Mil.


Incyte Loans Receivable Historical Data

The historical data trend for Incyte's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Loans Receivable Chart

Incyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Incyte Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Incyte Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Incyte Loans Receivable Related Terms

Thank you for viewing the detailed overview of Incyte's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Incyte Business Description

Traded in Other Exchanges
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.